Biotinylated Human EDNRA Full Length Protein (VLP)

Customer Reviews
Cat. No. / Size
Price
Qty
EDA-H82P3-20ug
$620.00
EDA-H82P3-100ug
$1235.00
EDA-H82P3-500ug (250ug X 2)
$4305.00
EDA-H82P3-1mg (250ug X 4)
Inquiry
ETA of in-stock products:2 business days

Product Details

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    endothelin receptor type A, ETA, ET-A, ETAR, ETRA, MFDA, ETA-R, hET-AR

  • Source

    Biotinylated Human EDNRA Full Length Protein (VLP) (EDA-H82P3) is expressed from human 293 cells (HEK293). It contains AA Asp 21 - Asn 427 (Accession # P25101-1).

    Predicted N-terminus: Asp

  • Molecular Characterization

    *The isotype control of empty/mock VLP (Cat. No. VLP-N82P3) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Labeling

    The VLP is biotinylated with proprietary technology.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-ELISA

     EDNRA ELISA

    Immobilized Biotinylated Human EDNRA Full Length Protein (VLP) (Cat. No. EDA-H82P3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-EDNRA Antibody, Human IgG1 (AM431) with a linear range of 0.5-63 ng/mL (QC tested).

    Protocol
  • Identity-DLS

     EDNRA DLS

    The mean peak Radius of VLP is 65-85 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Customer Reviews
Writing Reviews

Background

This gene encodes the receptor for endothelin-1, a peptide that plays a role in potent and long-lasting vasoconstriction. This receptor associates with guanine-nucleotide-binding (G) proteins, and this coupling activates a phosphatidylinositol-calcium second messenger system. Polymorphisms in this gene have been linked to migraine headache resistance. Alternative splicing results in multiple transcript variants.

Recent Advances

 
Drug Development Progress
  • English Name:

    Endothelin receptor type A

  • Category:

  • Approved Drugs:

    8 Details

  • Drugs in Clinical Trials:

    9 Details

  • Highest Development Stage:

    Approved

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background